{"product_id":"lemaitre-five-forces-analysis","title":"LeMaitre Vascular Porter's Five Forces Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDon't Miss the Bigger Picture\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eLeMaitre Vascular operates in a niche medical-device market where supplier specialization, regulatory barriers, and moderate buyer power shape competitive dynamics; innovation and distribution reach are key to sustaining margins and deterring entrants.\u003c\/p\u003e\n\u003cp\u003eThis brief snapshot only scratches the surface. Unlock the full Porter's Five Forces Analysis to explore LeMaitre Vascular’s competitive dynamics, market pressures, and strategic advantages in detail.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euppliers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Raw Material Requirements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLeMaitre Vascular depends on bovine pericardium and high-grade polymers for grafts and patches; these inputs must meet FDA\/CE standards, shrinking the pool of qualified suppliers to roughly a dozen global firms as of Q4 2025.\u003c\/p\u003e\n\u003cp\u003eThat supplier scarcity gives vendors moderate pricing leverage—industry estimates show raw-material cost inflation added about 3–5% to COGS for vascular device makers in 2024–2025.\u003c\/p\u003e\n\u003cp\u003eDelivery timing also matters: supplier lead times averaged 12–16 weeks in 2025, increasing inventory carrying costs and constraining production flexibility for LeMaitre.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStringent Regulatory Compliance Standards\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSuppliers in vascular medical devices must meet ISO 13485 and FDA QSR (21 CFR Part 820); noncompliance risks recalls and fines—FDA 2024 warning letters to device firms rose 18% year-over-year. \u003c\/p\u003e\n\u003cp\u003eAny supplier change forces LeMaitre Vascular into re-validation, often taking 6–12 months and costing $200k–$1M per component validation, so vendor switches are costly. \u003c\/p\u003e\n\u003cp\u003eThis validation lock-in raises supplier bargaining power, constraining LeMaitre’s sourcing flexibility and potentially raising input costs by several percentage points of COGS. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Switching Costs for Manufacturers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHigh switching costs protect LeMaitre Vascular because vascular-device specs are exacting, so raw components are often custom-made to its proprietary designs; qualifying a new supplier in medtech can take 6–12 months and cost $200k–$1m in validation, testing, and regulatory paperwork.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConcentration of Niche Biological Providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpin the biological tissue segment only a few certified suppliers can meet fda traceability and sterility standards for human implantation concentrating bargaining power raising lemaitre vascular supply risk single disruption could force costly delays or qualify exemptions. here quick math: if one supplier supplying of type halts shipments substitution lead time often exceeds months driving\u003e5% revenue-at-risk for affected product lines.\n\u003cp class=\"lst_crct\"\u003e\n\u003c\/p\u003e\u003cli\u003eFew certified suppliers: high concentration\u003c\/li\u003e\n\u003cli\u003eSingle-supplier share: 30–50% typical\u003c\/li\u003e\n\u003cli\u003eSubstitution lead time: 6–12 months\u003c\/li\u003e\n\u003cli\u003eRevenue-at-risk: \u0026gt;5% for impacted lines\u003c\/li\u003e\n\n\u003c\/pin\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLimited Threat of Forward Integration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSuppliers can press LeMaitre Vascular via scarce specialized materials, but they lack the clinical know-how and FDA\/CE regulatory setups needed to make finished vascular devices; as of 2025, \u0026gt;70% of device approvals require clinical data that raw-material firms rarely fund.\u003c\/p\u003e\n\u003cp\u003eHigh certification costs (median pivotal trial \u0026gt;$3–5M) and quality-system investments keep wholesalers from entering; supplier forward integration risk for LeMaitre remains very low.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eClinical\/regulatory barrier: median pivotal trial $3–5M\u003c\/li\u003e\n\u003cli\u003eApproval burden: \u0026gt;70% approvals need clinical evidence\u003c\/li\u003e\n\u003cli\u003eMaterial scarcity: suppliers hold pricing leverage\u003c\/li\u003e\n\u003cli\u003eForward-integration threat: low for LeMaitre\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConcentrated Suppliers, High Switch Costs: \u0026gt;5% Revenue at Risk from 12 Vendors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSupplier power: concentrated certified suppliers (≈12 global for bovine\/performance polymers in 2025) give moderate pricing leverage (raw-material inflation +3–5% COGS in 2024–25), long lead times (12–16 weeks) and high switching costs (validation 6–12 months, $200k–$1M), creating \u0026gt;5% revenue-at-risk if a 30–50% tissue supplier halts shipments.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (2025)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eQualified suppliers\u003c\/td\u003e\n\u003ctd\u003e≈12\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRaw-material inflation\u003c\/td\u003e\n\u003ctd\u003e+3–5% COGS\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLead time\u003c\/td\u003e\n\u003ctd\u003e12–16 weeks\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSwitch cost\u003c\/td\u003e\n\u003ctd\u003e$200k–$1M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue at risk\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eTailored Porter's Five Forces assessment of LeMaitre Vascular that uncovers competitive drivers, buyer and supplier leverage, threat of substitutes and new entrants, and identifies disruptive trends affecting pricing and profitability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCompact Porter's Five Forces view for LeMaitre Vascular—quickly spot supplier, buyer, and competitive pressures to inform M\u0026amp;A, pricing, and product strategy decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsolidation of Hospital Purchasing Systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cplarge hospital systems and integrated delivery networks have consolidated purchasing to win volume-based contracts using procedure volume demand discounts that squeeze supplier prices.\u003e\n\u003cplemaitre vascular faces growing margin pressure as these buyers secured roughly of cardiac and surgery spend in many us regions by leveraging scale to push average price cuts on standard devices.\u003e\n\u003cpby this trend continues to compress lemaitre gross margins on commoditized products contributing slower revenue growth unless the company shifts differentiated offerings or service bundles.\u003e\n\u003c\/pby\u003e\u003c\/plemaitre\u003e\u003c\/plarge\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInfluence of Group Purchasing Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGroup Purchasing Organizations (GPOs) negotiate contracts for over 70% of US hospitals, bundling demand to force price-based bidding; in 2024 top GPOs drove supplier rebates exceeding $10bn industry-wide.\u003c\/p\u003e\n\u003cp\u003eFor LeMaitre Vascular, securing GPO-approved vendor status is critical: losing access can cut reachable hospital revenue by an estimated 40–60% for specific product lines.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSurgeon Preference and Clinical Loyalty\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDespite hospital cost-cutting, vascular surgeons exert strong clinical preference: surveys show 68% of surgeons cite device familiarity as the top factor in device choice (2024 SCAI data), and in complex procedures surgeons are the de facto purchasers for catheters and grafts. This surgeon loyalty shields LeMaitre Vascular from pure price competition, supporting its 2024 gross margin of ~64% by preserving premium product usage. Hospitals press for savings, but surgeon choice limits switching to lowest-cost suppliers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLow Switching Costs for Commodity Products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eFor commodity items like basic catheters and balloons, hospitals can switch brands easily, driving strong price sensitivity; industry data shows commoditized disposables often see \u0026gt;30% supplier turnover annually in some systems (2024 NHS\/US group purchasing reports).\u003c\/p\u003e\n\u003cp\u003eLeMaitre counters by prioritizing specialized, higher-margin devices—these require clinician training and integration into care pathways, reducing switching; products in its vascular access and valve repair niches command gross margins 10–20 percentage points above commoditized lines (2024 company disclosures).\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh supplier churn \u0026gt;30% in commoditized disposables (2024)\u003c\/li\u003e\n\u003cli\u003ePrice-driven migration to lowest-cost providers\u003c\/li\u003e\n\u003cli\u003eLeMaitre focuses on specialized products with clinician lock-in\u003c\/li\u003e\n\u003cli\u003eSpecialized product margins ~10–20 pp higher (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTransparency in Reimbursement Rates\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpgovernment and private insurers set fixed reimbursement rates for vascular procedures national average payments peripheral bypass were about in hospitals device budgets are capped.\u003e\n\u003cpwhen rates stay flat or decline hospitals push harder for price cuts evidenced by device procurement discounting in group purchasing trends.\u003e\n\u003cptransparency forces lemaitre vascular to prove cost-effectiveness and clinical superiority across its portfolio avoid margin pressure.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMedicare avg payment: ~$10,200 (peripheral bypass, 2024)\u003c\/li\u003e\n\u003cli\u003eHospital device discounting: 8–12% (2023)\u003c\/li\u003e\n\u003cli\u003eLeMaitre must show lower total cost of care and superior outcomes\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/ptransparency\u003e\u003c\/pwhen\u003e\u003c\/pgovernment\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLeMaitre fights GPO price pressure by pivoting to higher‑margin specialized devices\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cphospitals and gpos wield strong bargaining power controlling of vascular spend driving price cuts which pressures lemaitre commoditized margins surgeon preference cite familiarity preserves premium device pricing supports gross margin. strategy: shift mix to specialized devices with pp higher secure gpo contracts protect access.\u003e\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospital\/GPO share of spend\u003c\/td\u003e\n\u003ctd\u003e60–70% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAverage device price cuts\u003c\/td\u003e\n\u003ctd\u003e8–12% (2023–24)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSurgeon preference\u003c\/td\u003e\n\u003ctd\u003e68% (2024 SCAI)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLeMaitre gross margin\u003c\/td\u003e\n\u003ctd\u003e~64% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialized product premium\u003c\/td\u003e\n\u003ctd\u003e+10–20 pp (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/phospitals\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eLeMaitre Vascular Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact LeMaitre Vascular Porter’s Five Forces analysis you'll receive immediately after purchase—no surprises, no placeholders.\u003c\/p\u003e\n\u003cp\u003eThe document displayed here is the part of the full, professionally formatted version you’ll get—ready for download and use the moment you buy.\u003c\/p\u003e\n\u003cp\u003eYou're looking at the actual, final file; once you complete your purchase, you’ll have instant access to this same, fully prepared analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56747174330745,"sku":"lemaitre-five-forces-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/lemaitre-five-forces-analysis.png?v=1772195610","url":"https:\/\/growthsharematrix.com\/products\/lemaitre-five-forces-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}